U.S. stock market quick update: 20/20 Biolabs launched a new product but failed to boost its stock price, instead suffering a 28.20% plunge. Where is the market confidence?

U.S. Stock Market Midday Update 20/20 Biolabs fell 28.20%. Based on recent key news: On February 25, 20/20 Biolabs launched a longevity blood test and chronic disease risk assessment and management solution based on IBM AI capabilities. This move aimed to expand the company's product line and enhance market competitiveness, but failed to immediately boost the stock price, instead raising investor concerns about the market acceptance of the new product, leading to a significant drop in stock price. On February 25, the company stated in a forward-looking statement that while it is optimistic about future results, it cannot guarantee achieving the expected outcomes. This statement exacerbated market uncertainty regarding the company's future performance, further depressing the stock price. There are doubts about the market acceptance of the new product, increasing risks. Stocks with High Trading Volume in the Industry Alcon rose 2.20%. Based on recent news: On February 24, Alcon released a strong Q4 2025 earnings report, with sales growth of 9%, reaching $2.7 billion, driving the stock price up. Source: Reuters On February 24, Alcon projected a net sales growth of 5% to 7% for 2026, with core diluted earnings per share growth of 9% to 12%, instilling confidence in the company's future performance. Source: Reuters On February 24, Alcon announced the launch of a new product, PanOptix Pro, which performed well in the U.S. market, further boosting investor confidence. Source: Reuters The medical device industry is performing strongly overall, with high demand for innovative products. Medline rose 1.37%, with a trading volume of $52.09 million. Based on recent key news: On February 25, Medline reported its full-year 2025 results, with net sales growth of 11.5%, but net income fell by 3.6%. Despite the decline in net income, increased customer confidence drove the stock price up. Source: Benzinga On February 25, Medline CEO Jim Boyle stated that the IPO will drive the company’s continued investment for growth, expecting organic sales growth of 8% to 9% in 2026. This optimistic outlook boosted market sentiment. Source: SEC filings On February 25, Medline signed a major supplier agreement with McLaren Health Care, expanding its product portfolio and distribution network, enhancing market competitiveness. Source: Public Technologies The healthcare industry is experiencing strong growth, with a focus on cost pressures. Aiqi Technology rose 0.82%. Based on recent key news: On February 23, Aiqi Technology's financial report showed a revenue growth of 5.3%, exceeding analyst expectations by 1.2%. This positive financial result drove the stock price up by 8.9%. Source: Zhitong Finance On February 23, the overall performance of the medical equipment and supplies industry was poor, with an average stock price decline of 3.4% over the past month. However, Aiqi Technology performed exceptionally well during this period, with a stock price increase of 0.82%. Source: Wall Street Insight On February 23, concerns about potential tariff and corporate tax changes led to industry volatility, but Aiqi Technology's robust performance alleviated some investor worries. Source: Jinshi Data The medical equipment industry has recently performed poorly, with increased volatility. Stocks ranked at the top of the industry by market capitalization Cooper Medical fell 0.90%. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation. no_news